Drug Profile
Indapamide/nebivolol
Alternative Names: Nebivolol/indapamideLatest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Antihypertensives; Benzopyrans; Ethanolamines; Indoles; Ischaemic heart disorder therapies; Small molecules; Sulfonamides
- Mechanism of Action Beta 1 adrenergic receptor antagonists; Thiazide-like diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 01 Nov 2018 Chemical structure information added
- 11 Oct 2018 No recent reports on development identified- phase III for Hypertension in India (PO)